VERU: Veru Inc. Projected Sales Volume

Veru Inc - graphic logo of issuer VERU

Veru Inc. current cash flow is based on the sale of urological products, as reflected in the organization's projected sales trends. The value of 0.00 determines the current status of the parameter. Partnerships with breast cancer therapy medical centers are accelerating business growth, however, the biotech's success relies on the test results of anti-obesity drugs and available capital.

Company Future Revenue: verupharma.com (VERU) for 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Veru Pharma (VERU)

- current price and projected stock value:
Basic company analysis:VERU Veru Pharma
Product sample of Veru Inc

The development of Veru Inc. (VERU) depends directly on the clinical efficacy of its prostate and breast cancer drugs. This indicator reflects the current discounted present value of all projected cash flows, accounting for the cost of capital. By analyzing the firm's sales volume expectations, an investor gains an objective assessment of future healthcare product revenue. The break in the curve on this chart signals a shift in the long-term trend. This metric allows investors to avoid premature entry into the asset before a fundamental reversal is confirmed.

Who Veru Inc. competes with

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Company Future Sales Volume|Accuray Inc. (ARAY) - Company Expected Sales Volume|SELLAS Life Sciences Group, Inc. - Projected Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Company Projected Revenue|HURA - Company Future Sales|TARA (Protara Therapeutics, Inc.) - Projected Sales Volume|Projected Sales Volume Fate Therapeutics Inc|Projected Sales Volume WHWK|Projected Sales Volume TScan Therapeutics Inc (TCRX)|Company Projected Revenue championsoncology.com CSBR|XBIT - Company Future Sales Volume|CVM - Company Projected Revenue|Company Future Revenue OSTX (OS Therapies)|RADX: Projected Sales Volume|Artiva Biotherapeutics Inc. - Company Future Revenue|ANL (Adlai Nortye) - Projected Sales Volume|Company Expected Sales Volume Tempest Therapeutics, Inc. TPST|Projected Sales Volume XLO|Renovaro - Company Revenue Forecast|Company Projected Revenue Mural Bio MURA|KAPA: Company Revenue Forecast|OnKure Therapeutics - Projected Sales Volume|Company Future Sales w2.cytomed.sg GDTC|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics Inc.|THAR (Tharimmune Corporation) - Projected Sales Volume|Projected Sales Volume Advanced Biomed Inc|Projected Sales Volume GNPX|Company Future Sales Volume Calidi Biotherapeutics Inc. CLDI|Company Projected Revenue Sunshine Biopharma Inc. SBFM|Company Future Sales Xenetic Biosciences (XBIO)|SLRX - Company Projected Revenue|Company Expected Sales Volume Kitov Pharma|AON (AONC) - Company Projected Revenue|Company Future Sales Volume BeiGene|Company Projected Revenue checkpointtx.com|Company Revenue Forecast ELEV (Elevation Oncology)|Projected Sales Volume ICAD|Ikena Oncology - Company Revenue Forecast|Company Projected Revenue Notable Labs, Ltd. NTBL|VIRX: Company Revenue Forecast|MOR - Company Projected Revenue|NAYA Bio (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume